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Arsenic contamination of drinking water is a
worldwide public health concern. The extent of
the concern in some countries has reached a
point such that some are calling this humanity’s
largest mass poisoning (Bhattacharjee 2007).
Even low levels of exposure to arsenic have
been linked to increased cardiovascular disease
and hypertension (Chen et al. 2007; Navas-
Acien et al. 2005). Although natural contami-
nation of drinking water with inorganic arsenic
represents the largest arsenical hazard to human
health, environmental exposure to commercial
organoarsenicals is a growing concern (Sapkota
et al. 2007). Organoarsenicals such as roxarsone
are widely used by the poultry industry (Arai
et al. 2003; Brown et al. 2004; Chapman et al.
2002), with approximately 2.2 million pounds
of roxarsone being fed to broiler chickens raised
in the United States per year (Garbarino et al.
2003). The majority of roxarsone is excreted
unchanged from chickens (Morrison 1969),
while the remainder increases the total arsenic
present in chicken tissue (Lasky et al. 2004).
This residual roxarsone could amount to inges-
tion of 1.38–5.24 mg/day of arsenic at mean
levels of chicken consumption (60 g/person/
day) (Wallinga 2006). The excreted roxarsone
may pose an environmental hazard, as
microbes, including those residing in the gut
microﬂora, can release inorganic arsenite (AsIII)
from roxarsone (Stolz et al. 2007). The human
health impacts of roxarsone have not been well
studied, and the mechanisms for its biological
effects in mammalian tissues are unknown. It
has been suggested, however, that all of these
biological effects require metabolism to inor-
ganic AsIII (O’Connor et al. 2005).
In a variety of in vivo and in vitro models,
nanomolar or low micromolar concentrations
of arsenic (AsIII) stimulate angiogenesis and
vascular remodeling that may promote vascular
diseases and tumorigenesis (Kamat et al. 2005;
Liu et al. 2006; Soucy et al. 2003, 2005).
In addition to enhancing tumor growth,
increased angiogenesis would contribute to
overall growth potential and increased tissue
pigmentation. These are the attributes of rox-
arsone that contribute to its widespread use;
however, the cellular effects of roxarsone to
mammalian cells are not known. Further, it is
unclear whether the vascular effects of roxar-
sone are dependent on its metabolism to inor-
ganic arsenic. Herein we report the angiogenic
potential of roxarsone and compare it with
that of inorganic arsenite (AsIII). In addition,
we report different modes of action of these
two compounds in promoting angiogenesis. 
Materials and Methods 
Culture of endothelial cells. Human aortic
endothelial cells (HAEC) and lung micro-
vascular endothelial cells (HMVEC) (Clonetics;
Lonza, Walkersville, MD, USA) were cultured
at 5% CO2 in complete MCDB 131 medium
(Invitrogen, Carlsbad, CA, USA) supplemented
with 5% fetal calf serum (Hyclone; Thermo
Fisher Scientific, Pittsburgh, PA, USA),
1% pen/strep, 1% hydrocortisone, 2 mM L-glu-
tamine, and 10 ng/mL epidermal growth factor
(Sigma-Aldrich Chemical Co., St. Louis, MO,
USA). Under these conditions up to 10 μM
roxarsone was not cytotoxic, as determined by
dye exclusion assays, whereas AsIII was toxic at
10 μM but not at 5 μM (Barchowsky et al.
1999a). Cells were used at passages 6–7 in
three-dimensional Matrigel matrix cultures to
probe the angiogenic potential (tube formation)
of roxarsone and AsIII.
Three-dimensional angiogenic tube-
formation assay. Concentration-responsive
effects of roxarsone and AsIII on the angiogenic
potential of HAEC and HMVEC were com-
pared in quantitative high-content cellular
imaging tube-formation assays in Matrigel
(BD Biosciences, San Jose, CA, USA). Cells
were incubated for 24 hr in reduced serum and
growth factor MCDB 131 (1:5 dilution of
complete MCDB 131 with nonsupplemented
MCDB 131). The cells were then released
from the culture dish with trypsin, diluted in
MCDB 131 with or without inhibitors, and
6,000–10,000 cells were plated onto 35-mL
Matrigel cushions in 96-well plates. Sodium
arsenite (AsIII)) or roxarsone was then added
from 1,000× stock solutions. As positive
controls for angiogenic tube formation, either
vascular endothelial growth factor (1 ng/mL)
or a cocktail of growth factors (vascular
endothelial growth factor, 10 ng/mL; fibro-
blast growth factor, 10 ng/mL; erythropoietin,
2 U/mL; and interleukin-6, 10 ng/mL)
were added to the cultures. After 16 hr, the
medium was removed and the gels were air
dried. Rhodamine-labeled phalloidin and
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BACKGROUND: Roxarsone (3-nitro-4-hydroxy benzene arsonic acid) is an arsenic compound widely
used in the poultry industry as a feed additive to prevent coccidiosis, stimulate growth, and to improve
tissue pigmentation. Little is known about the potential human health effects from roxarsone released
into the environment from chicken waste or from residual compound in chicken products.
OBJECTIVE: The growth potentiation and enhanced tissue pigmentation suggest that low levels of
roxarsone exposure may have an angiogenic potential similar to that of inorganic arsenite (AsIII).
The goal of this investigation was to test the hypothesis described above using cultured human aor-
tic and lung microvascular endothelial cells in high-content imaging tube-forming assays and begin
developing a molecular level understanding of the process.
METHODS: We used a three-dimensional Matrigel assay for probing angiogenesis in cultured
human endothelial cells, and a polymerase chain reaction (PCR) array to probe the gene changes as
a function of roxarsone or AsIII treatment. In addition, we used Western blot analysis for changes in
protein concentration and activation. 
RESULTS: Roxarsone was found to exhibit a higher angiogenic index than AsIII at lower concentra-
tions. Increased endothelial nitric oxide synthase (eNOS) activity was observed for roxarsone but not
for AsIII-induced angiogenesis. However, AsIII caused more rapid and pronounced phosphorylation
of eNOS. Quantitative PCR array on select genes revealed that the two compounds have different
and often opposite effects on angiogenic gene expression.
CONCLUSIONS: The results demonstrate that roxarsone and AsIII promote angiogenic phenotype in
human endothelial cells through distinctly different signaling mechanisms.
KEY WORDS: angiogenesis, animal feed, arsenic, gene expression, nitric oxide, roxarsone, tube
formation. Environ Health Perspect 116:520–523 (2008). doi:10.1289/ehp.10885 available via
http://dx.doi.org/ [Online 17 January 2008]4´-6-diamidino-2-phenylindole (DAPI;
(Sigma-Aldrich) were added to stain F-actin
and nuclei, respectively. Images of ﬂuorescently
labeled cells were collected with a Thermo
Scientific Cellomics ArrayScan HCS Reader
(Thermo Fisher Scientific, Pittsburgh, PA,
USA) and analyzed by an automated algorithm
that identiﬁed the tubes formed by the associa-
tion and clustering of the endothelial cells.
This algorithm provided quantitative measure-
ments of tube properties such as the number of
tubes, tube lengths, tube areas, number of
nodal branch points, and the angiogenic
index—deﬁned as the percentage of image area
covered by tubes multiplied by 10 (Ghosh
et al. 2007; Grove and Ghosh 2006). Each
experiment was repeated 3 times, and each
treatment was probed in at least six wells.
Differences between treatments were analyzed
by one- and two-way analysis of variance
(ANOVA) and Dunnett or Bonferroni post
hoc tests for significance using Graphpad
Prism v4.0 software (Graphpad Software,
San Diego, CA, USA).
SuperArray Angiogenesis RT2 Profiler
PCR array. The effects of 24-hr exposures to
AsIII and roxarsone on HMVEC mRNA levels
for 84 angiogenic and 5 constitutive genes
were measured using the SuperArray quantita-
tive polymerase chain reaction (PCR) assay
(SuperArray Bioscience Corp., Frederick,
MD, USA). Total RNA was extracted from
approximately 500,000 cells using QIAGEN
RNeasy (QIAGEN, Chatsworth, TN, USA)
mini kits with inclusion of a DNase treatment
step. First-strand cDNA synthesis and quanti-
tative real-time PCR with SYBR green master
mix was performed in an Opticon 2 DNA
engine (BioRad Corp., Hercules, CA, USA)
according to the manufacturer’s instructions.
Western analysis. Western blot analysis
was performed on proteins isolated from
HAEC exposed to AsIII or roxarsone for 0.5,
1, or 4 hr. The proteins were separated by
sodium dodecyl sulfate–polyacrylamide gel
electrophoresis and transferred to polyvinyli-
dene membranes, as previously described
(Barchowsky et al. 1999b). Blots were probed
with primary antibody to either total or
ser1177 phosphorylated eNOS (Cell Signaling
Technologies, Danvers, MA, USA) and
reacted bands were detected by horseradish
peroxidase–conjugated secondary antibodies
and enhanced chemiluminescence substrates
(PerkinElmer, Boston, MA, USA). Density of
bands on film exposed to blots was deter-
mined using Scion Image software (Scion
Corp., Frederick, MD, USA).
Results and Discussion
Concentration-responsive effects of roxarsone
and AsIII on the angiogenic potential of
HAEC and HMVEC were compared in
quantitative high-content cellular imaging
tube-formation assays in Matrigel (Figure 1).
Images of ﬂuorescently labeled cells were ana-
lyzed by an algorithm that identified the
angiogenic tubes formed by the association
and clustering of the endothelial cells and
quantitatively measured the properties of the
identiﬁed tubes such as the number of tubes,
tube lengths, tube areas, number of nodal
branch points, and the angiogenic index. The
angiogenic index is deﬁned as the percentage
of image area covered by tubes multiplied by
10 (Ghosh et al. 2007; Grove and Ghosh
2006). Both compounds were as effective as
vascular endothelial cell growth factor
(VEGF) in increasing the angiogenic index
above the value for untreated control cells in
both cell types (Figures 1 and 2). Both cell
types exhibited strong angiogenic responses
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Figure 1. Images of ﬂuorescent-labeled HAEC (10,000 cells/well) treated with different concentrations of
roxarsone. HAEC were grown on a thin layer of Matrigel in a 96-well plate, treated for 16 hr, then ﬁxed and
ﬂuorescently labeled with rhodamine–phalloidin (λex ~ 542 nm, λem ~ 565 nm) to delineate the cell and tube
structures. Images were acquired on a Thermo Scientific Cellomics ArrayScan HCS Reader using a 5×
microscope objective (lengths of images shown are 1,400 µm, and scale bar in the negative control panel
is 350 µm), and analyzed by an automated algorithm for quantifying tube morphology. Grayscale ﬂuores-
cence images are shown with colored overlays from the algorithm identifying the different entities meas-
ured: connected tubes are outlined in blue, unconnected objects are in aqua, nodes where the tube
branches are marked by pink dots, and objects rejected from the quantitative analysis are in orange.
A B
C D
Figure 2. Angiogenic index obtained directly from
the image processing of the tube formation assay
on HAEC. “No treatment” refers to the negative
control, which had no treatment, and the cells were
grown on serum-free basal media; GF refers to a
mixture of growth factors used as a positive control
(VEGF, 10 ng/mL; ﬁbroblast growth factor, 10 ng/mL;
erythropoietin, 2 U/mL; and interleukin-6, 10 ng/mL).
As and Rox refer to AsIII and roxarsone, respec-
tively. In each case, data were collected from six
wells, and ﬁve different ﬁelds were imaged for each
well. The angiogenic index ± SD is plotted for each
condition. Error bars indicate SDs. 
*p < 0.05 and **p < 0.01 determined from one-way ANOVA







































*with the arsenical treatments; however, the
HMVEC showed a higher basal level of
angiogenesis (Table 1). Because of their lower
basal angiogenic activity, HAEC were used
for additional mechanistic studies. 
The angiogenic threshold for roxarsone
was between 0.001 and 0.01 μM, an order of
magnitude lower than the threshold for AsIII
(Figures 1 and 2). As we have previously
shown in in vivo chicken allantoic membrane
angiogenesis assays (Soucy et al. 2003), above
1 μM AsIII becomes toxic to tube formation
and inhibits angiogenesis (Figure 2). In con-
trast, even 10 μM roxarsone showed no
decrease in the angiogenic index (Figures 1
and 2) or signs of toxicity in the endothelial
cells (data not shown). The fact that the efﬁ-
cacy for tube formation was similar, but the
toxic potential differs, suggested that the two
arsenicals differ in their mechanisms of action.
Nitric oxide (NO) production is required
for certain stimuli to promote angiogenesis
(Yu et al. 2005), but AsIII is known to pro-
mote reactive oxygen that limits available NO
release in endothelial cells (Barchowsky et al.
1999a, Bunderson et al. 2006). The data in
Figure 3 demonstrate that roxarsone requires
NO generation to increase angiogenesis. Its
effects were blocked by the eNOS inhibitor
L-NG-nitroarginine methylester (L-NAME),
but not its inactive enantiomer D-NG-
nitroarginine methylester (D-NAME). In
contrast, both NAME enantiomers prevented
AsIII from increasing the angiogenic index.
This would suggest either that AsIII inhibition
by NAME was a nonstereospecific chemical
effect or that D-NAME interacted with AsIII
in a unique manner relative to roxarsone.
Thus, roxarsone and inorganic AsIII appeared
to have differential effects on signaling for
NO-mediated angiogenesis. 
To investigate a possible mechanism for
increased eNOS activity after exposure to
arsenicals, we exposed HAEC to either roxar-
sone or AsIII for 0.5–4 hr, then probed for
levels of serine phosphorylated eNOS relative
to total eNOS. As shown in Figure 4, both
arsenicals caused time-dependent increases in
Ser1177 phosphorylation of eNOS. However,
roxarsone caused a progressive increase over
4 hr, whereas AsIII caused a rapid stimulation
of phosphorylation that was declining by
4 hr. These data indicate that the arsenicals
do not share similar common upstream sig-
naling actions that enhance the activity of
AKT, a serine/threonine protein kinase,
which commonly accounts for serine phos-
phorylation (Dimmeler et al. 1999; Fulton
et al. 1999). In addition, the time course for
the effects of AsIII is consistent with its known
ability to stimulate vascular NADPH oxidase
to generate superoxide that quenches NO to
form peroxynitrite (Bunderson et al. 2002;
Lynn et al. 2000; Smith et al. 2001). These
oxidants often mediate inflammatory angio-
genesis (Ushio-Fukai and Alexander 2004)
and thus may account for the mechanism of
action for AsIII. 
Analysis of the effects of the two arsenicals
on angiogenic gene activity further indicated
that roxarsone and AsIII signal through distinct
but overlapping mechanisms. Superarray quan-
titative PCR arrays of total RNA extracts from
HMVEC treated with either arsenical for 24 hr
demonstrated that the arsenicals differentially
affect expression of a limited set of 9 of 84
inducible genes measured. AsIII induced more
genes than it inhibited (Table 2). At 0.1 μM,
roxarsone inhibited more genes than it induced
(Table 2). Several genes were affected in the
same direction, but not to the same degree by
the two agents. Both arsenicals decreased angio-
genic repressive interferon 1α (Strieter et al.
2005) and interferon-inducible CXCL9 tran-
scripts. It was interesting that generally the
higher roxarsone concentration (1.0 μM) had
either no effect on gene expression or the
opposite effect of the low concentration. The
Basu et al.
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Table 1. Angiogenic index of the response to arsenicals by different endothelial cells.
HAEC HMVEC
Treatment Mean ± SD Negative control (%) Mean ± SD Negative control (%)
No treatment (negative control) 15 ± 3 100 95 ± 62 100
Growth factor (positive control) 35 ± 28 239 125 ± 75  132
AsIII (0.1 µM) 32 ± 29 223 146 ± 81 155
Roxarsone (0.1 µM) 28 ± 9 191 198 ± 95 210
Figure 3. Effects of L-NAME (A) and D-NAME (B) on angiogenic index. HAEC were treated as follows:
(a) no treatment, (b) a mixture of growth factors as a positive control, (c) roxarsone (0.1 µM), and (d) AsIII
(0.1 µM). Open bars represent cells with no NAME; blue bars represent cells treated with different isomers
of NAME (50 µM). In each case, 12 wells were investigated, and each well was imaged at five different
ﬁelds. Angiogenic index ± SD is plotted in each case. 
















































(a) (b) (c) (d) (a) (b) (c) (d)
L-NAME D-NAME
*** A B
Figure 4. Western blot showing phosphorylated eNOS (p-eNOS) (A), and total eNOS (B) in HAEC. Proteins
were loaded equally after protein determination, which was confirmed by probing beta-actin (data not
shown). Conditions: NC, no additional treatment; GF, a mixture of grown factors as positive control as
described in Figure 2; Rox, 1 µM roxarsone; As, 1 µm AsIII. All lanes on the gels were generated using
proteins from separate cell cultures. Two replicates were done for each condition and were also used for
statistical analyses. Individual bands were analyzed using Scion Image program, and the percent eNOS
phosphorylated with respect to total is plotted for each condition (mean ± SD). 
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exception was the concentration-dependent
induction of hepatocyte growth factor (HGF)
mRNA levels by both roxarsone concentra-
tions. AsIII also strongly induced HGF tran-
scripts. It is difﬁcult to reconcile the differential
effects of AsIII and the two concentrations of
roxarsone on gene expression with their con-
centration-dependent effects on angiogenic
potential. It is possible that induction of a dom-
inant factor, such as HGF, accounted for the
observed increases in tube formation. However,
the analysis was limited by the small number of
gene changes measured and a lack of informa-
tion regarding protein changes that may
account for increased angiogenic index.
Although beyond the scope of the current stud-
ies, additional mechanistic experiments would
delineate the linkage between any gene or pro-
tein change and increased angiogenic index
after arsenical exposure. Nonetheless, these data
demonstrate that roxarsone and inorganic AsIII
signal through different mechanisms to affect
induction of genes that regulate angiogenesis.
Conclusion
Our results in human endothelial cell cultures
demonstrate that roxarsone was a more potent
inducer of angiogenesis than inorganic AsIII,
and that roxarsone and AsIII signal through
separate pathways to promote angiogenesis.
The arsenicals had different time courses for
phosphorylating eNOS; only the effects of
roxarsone were blocked speciﬁcally by eNOS
inhibition, and the two arsenicals differentially
affected angiogenic gene induction. In addi-
tion to these differential effects, the fact that
roxarsone is more potent for tube formation
and less cytotoxic supports the conclusion that
metabolism to inorganic AsIII cannot account
for its vascular effects. More importantly, this
was the ﬁrst demonstration of functional vas-
cular effects of roxarsone that may implicate a
disease risk. Future studies are needed to
demonstrate the mechanisms that enable dif-
ferential signaling by the two arsenicals and
the impact of this signaling in human
endothelial cells on vascular disease promoted
by their environmental exposures.
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Table 2. SuperArray Angiogenesis RT2 Proﬁler PCR array for angiogenic genes.
Fold control
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Leukocyte cell–derived chemotaxin 1 0.46 ± 0.23* 0.96 ± 0.20 0.55 ± 0.09*
Leptin 0.21 ± 0.08** 0.98 ± 0.43 0.57 ± 0.29
Plasminogen 0.31 ± 0.02** 0.84 ± 0.18 0.63 ± 0.30
Anti-angiogenic genes
Interferon 1α 0.34 ± 0.09* 1.14 ± 0.39 0.71 ± 0.32
CXCL9 0.17 ± 0.08** 1.03 ± 0.33 0.46 ± 0.13**
Approximately 500,000 HMVEC were incubated with roxarsone or AsIII for 24 hr. Extracted total RNA was then isolated
and mRNA levels for 84 inducible and 5 constitutive genes were measured, according to the manufacturer’s instructions.
Data are presented as mean ± SD fold over untreated control for PCR products normalized to housekeeping gene expression. 
*p < 0.05, **p < 0.01, and ***p < 0.001 (n = 6 separate RNA extracts).